Drug intelligence / Profile preview

GF-10054

Development stage: Preclinical
Lead developer: GenFlow Biosciences
Modality: Gene Therapies

Overview

GF-10054 is an investigational gene therapy candidate developed by Genflow Biosciences. It is one of a series of drug candidates (GF-10052, GF-10053, and GF-10054) that co-express centSIRT6 with other components. The specific mechanism involves the expression of centSIRT6, a variant of the SIRT6 gene associated with longevity and genomic stability. The primary indication for these candidates is not explicitly stated in the available information but relates to aging and age-related diseases based on Genflow's focus area[3].

Targets

SIRT2 (NAD-dependent protein deacetylase sirtuin-2)SIRT6 (Sirtuin 6)

Beyond the preview

Go deeper on GF-10054.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GF-10054.

Explore the full profile